Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCOSCIENS Biopharma Inc.

COSCIENS Biopharma Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.5 CAD 0.00(0%)
Last update at 2026-11-03T14:30:00Z
Market Cap
8.72M

Momentum Score

…

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.50
Low
8.50
High
52 Week Price Range
1.10
Low
6.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

COSCIENS Biopharma Inc. is a Canadian-listed biopharmaceutical company (CSCI.TO) with limited publicly available disclosure about its programs and operations. Long-term growth may depend on advancement of its development pipeline, licensing or partnership deals and successful regulatory milestones, which could support value creation for investors seeking exposure to early-stage biotech.

Key investment risks include high clinical and regulatory uncertainty, probable need for additional financing and low liquidity that could magnify downside for shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.50
Dividend Yield
-
Revenue TTM
7.50M
Revenue Per Share
2.37
Gross Profit TTM
2.57M
Debt / Equity
-
ROE
-121.84%
Net Debt
-
ROCE
-58.17%
Diluted EPS TTM
-4.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.35M -15.22M -4.45M 4.26M 2.59M
Net income -10.36M -15.31M -3.55M 3.24M 2.64M
Selling general administrative 10.06M 10.45M 5.62M 2.75M 2.58M
Gross profit 2.65M 4.73M 2.98M 8.12M 8.21M
Reconciled depreciation 1.19M - 1.47M 1.41M 1.48M
Operating income -10.37M -18.28M -4.72M 4.05M 2.59M
Interest expense 0.17M - 0.10M 0.10M 0.12M
Tax provision 0.01M 0.08M -0.90M 1.02M -0.05M
Interest income 0.28M 0.36M 0.33M 0.07M -
Net interest income 0.12M - 0.19M -0.07M -0.16M
Total revenue 7.50M 9.59M 7.26M 13.88M 13.49M
Total operating expenses 17.86M 27.87M 11.98M 9.83M 10.90M
Cost of revenue 4.85M 4.86M 4.28M 5.76M 5.28M
Total other income expense net -0.10M - 0.07M 0.27M 0.16M
Net income from continuing ops -10.36M - -3.55M 3.24M 2.64M
Net income applicable to common shares - -15.31M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21.43M 35.07M 23.70M 27.80M 24.35M
Intangible assets - 0.00M 0.01M 0.01M 0.01M
Other current assets 0.18M 0.21M - - -
Total liab 17.59M 21.91M 2.71M 4.01M 2.61M
Total stockholder equity 3.84M 13.16M 21.00M 23.79M 21.74M
Other current liab 1.12M - - - -
Common stock - 22.49M - - -
Capital stock 22.62M - 12.61M 12.30M 12.99M
Retained earnings -20.51M -12.11M 4.65M 8.02M 5.08M
Other assets - 0.12M - - -
Cash 7.31M 16.39M 6.67M 10.18M 6.10M
Total current liabilities 3.61M 7.22M 1.31M 1.55M 0.76M
Short term debt - 0.00M - - -
Other stockholder equity - -1.48M - - -
Property plant equipment - 10.97M - - -
Total current assets 11.50M 23.98M 11.19M 15.17M 9.73M
Net receivables 1.08M 1.88M 0.13M 2.08M 1.64M
Inventory 1.31M 2.69M 4.00M 2.77M 1.82M
Accounts payable 0.74M - - - -
Non currrent assets other 0.12M - 0.01M - -
Non current assets total 9.93M - 12.51M 12.63M 14.62M
Capital lease obligations 2.15M - 1.69M 1.93M 2.08M
Long term debt total - 2.04M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - -0.74M -0.29M -0.62M
Total cashflows from investing activities - 25.08M - - -
Net borrowings -0.36M - - - -
Total cash from financing activities -0.41M -0.59M -0.27M -0.16M -0.24M
Net income -10.36M -15.31M -3.55M -22.73M -8.37M
Change in cash -9.09M 9.71M -3.74M 4.44M 1.89M
Begin period cash flow 16.39M - 10.41M 5.73M 4.21M
End period cash flow 7.31M - 6.67M 10.18M 6.10M
Total cash from operating activities -8.47M -14.57M -2.73M 4.89M 2.75M
Depreciation 1.19M 1.61M 1.47M 1.41M 1.48M
Other cashflows from investing activities - 26.24M - - -
Change to inventory - - -1.17M -1.06M -0.87M
Change to account receivables - - 2.00M -0.54M -0.06M
Sale purchase of stock - -0.17M - - -
Capital expenditures 0.71M 1.16M 0.74M 0.29M 0.56M
Change in working capital 0.29M -1.77M 0.06M -0.84M -1.16M
Stock based compensation -0.01M - 0.20M 0.07M 0.01M
Other non cash items 0.05M - 0.10M 0.10M 0.12M
Free cash flow -9.18M - -3.47M 4.60M 2.20M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSCI
COSCIENS Biopharma Inc.		 -
-%		 8.50 - - 1.16 1.66 0.16 4.57
EPRX
Eupraxia Pharmaceuticals Inc		 -0.17
1.76%		 9.48 - - - 8.45 - -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 - 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 4422.35 -6.36

Profile*

COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

22 Adelaide Street West, Toronto, ON, Canada, M5H 4E3

843 900 3223

https://www.cosciensbio.com

28

Name Title Year Born
Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc. President, CEO & Director 1954
Mr. Giuliano La Fratta Senior VP of Finance & CFO NA
Dr. Michael Teifel Ph.D. Senior VP of Non-Clinical Development & Chief Scientific Officer NA
Dr. Nicola Ammer M.D. Chief Medical Officer & Senior VP of Clinical Development NA
Dr. Matthias Gerlach Senior Vice President Manufacturing and Supply Chain & Head of Production NA
Mr. Michel Regnier P. Eng. Senior VP of Technical operations, MD of Ceapro Inc. & CTO NA
Dr. Michael Teifel Ph.D. Senior Vice President of GmbH & Chief Scientific Officer NA
Ms. Anna Elizabeth Biehn Chief Executive Officer NA
Mr. Peter Harry Puccetti CFA Interim CEO & Independent Chairman NA
Dr. Klaus Paulini Ph.D. President & CEO NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…